Patents by Inventor Samuel D. BANISTER

Samuel D. BANISTER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES
    Publication number: 20210300877
    Abstract: A genus of compounds encompassed by formula (III) and their use is disclosed: The compounds activate Ppargc1a and, as a consequence, are useful for treating a variety of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, motor neuron diseases, and a demyelinating disease.
    Type: Application
    Filed: August 6, 2019
    Publication date: September 30, 2021
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Samuel D. BANISTER, Edgar ENGLEMAN, Khoa D. NGUYEN, Mark SMITH
  • 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases
    Patent number: 11111217
    Abstract: The compound 2-(4-tert-Butylphenyl)-1H-benzo[d]imidazol-5-ol: and its use are disclosed. The compound activates Ppargc1a and, as a consequence, is useful for treating neuroinflammation and for treating a variety of neurodegenerative diseases.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: September 7, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Samuel D. Banister, Edgar Engleman, Khoa D. Nguyen, Mark Smith
  • 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES
    Publication number: 20210061769
    Abstract: The compound 2-(4-tert-Butylphenyl)-1H-benzo[d]imidazol-5-ol: and its use are disclosed. The compound activates Ppargc1a and, as a consequence, is useful for treating neuroinflammation and for treating a variety of neurodegenerative diseases.
    Type: Application
    Filed: October 13, 2020
    Publication date: March 4, 2021
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Samuel D. BANISTER, Edgar ENGLEMAN, Khoa D. NGUYEN, Mark SMITH
  • 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases
    Patent number: 10851066
    Abstract: The compound 2-(3-tert-Butylphenyl)-4,6-difluoro-1H-benzo[d]imidazole and its use are disclosed: The compound activates Ppargc1a and, as a consequence, is useful for treating neuroinflammation and for treating a variety of neurodegenerative diseases.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: December 1, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Samuel D. Banister, Edgar Engleman, Khoa D. Nguyen, Mark Smith
  • 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES
    Publication number: 20200299244
    Abstract: The compound 2-(3-tert-Butylphenyl)-4,6-difluoro-1H-benzo[d]imidazole and its use are disclosed: The compound activates Ppargc1a and, as a consequence, is useful for treating neuroinflammation and for treating a variety of neurodegenerative diseases.
    Type: Application
    Filed: May 29, 2020
    Publication date: September 24, 2020
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Samuel D. BANISTER, Edgar ENGLEMAN, Khoa D. NGUYEN, Mark SMITH